Jefferies Maintains Buy on United Therapeutics, Raises Price Target to $432
Portfolio Pulse from Benzinga Newsdesk
Jefferies analyst Eun Yang has maintained a Buy rating on United Therapeutics and raised the price target from $315 to $432.
September 23, 2024 | 3:20 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Jefferies has increased its price target for United Therapeutics from $315 to $432, maintaining a Buy rating. This suggests a positive outlook for the company's stock.
The increase in the price target from $315 to $432 by Jefferies, along with the maintained Buy rating, indicates a strong positive sentiment from the analyst. This is likely to boost investor confidence and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100